NDAC Approach To OTC Switches Highlighted At Corticosteroid Meeting
This article was originally published in The Tan Sheet
Executive Summary
A joint FDA advisory committee meeting evaluating the Rx-to-OTC switch prospects of topical corticosteroids underscored the different approaches to switches taken by OTC drug advisors and more cautious prescribers with category-specific expertise